From: Assessment of anti-cyclic citrullinated peptide in psoriatic arthritis
 | Anti-CCP-positive (n = 7) | Anti-CCP-negative (n = 33) | P-value |
---|---|---|---|
Age (years) | Â | Â | Â |
Mean ± SD (range) | 43 ± 5.7 (39–50) | 47 ± 6.9 (33–54) | 0.161* |
Sex | Â | Â | Â |
Male n (%) | 3 (42.86%) | 15 (45.45%) | Â |
female n (%) | 4 (57.14%) | 18 (54.55%) | 0.67** |
Disease Duration (months) | Â | Â | Â |
Mean ± SD (range) | 40.7 ± 12.34 (30–54) | 37 ± 9 (24–60) | 0.36* |
PASI | Â | Â | Â |
Mean ± SD (range) | 10 ± 1.53 (8–11) | 8.86 ± 1.9 (7–13) | 0.146* |
Psoriatic nail changes | Â | Â | Â |
n (%) | 4 (57.14%) | 29 (87.9%) | 0.087** |
Involved joints | Â | Â | Â |
median (range) | 15 (10–24) | 6 (5–10) | 0.0135* |
Swollen joints | Â | Â | Â |
median (range) | 2.5 (2–7) | 1 (0–2) | 0.023* |
Tender joints | Â | Â | Â |
median (range) | 9 (3–16) | 3 (0–8) | 0.009* |
Spondyloarthritis | Â | Â | Â |
n (%) | 1 (14.28%) | 5 (15.15%) | 0.901** |
Oligoarthritis | Â | Â | Â |
n (%) | 0 | 6 (18.18%) | 0.567** |
Symmetric Polyarthritis | Â | Â | Â |
n (%) | 7 (100%) | 12 (36.36%) | 0.003** |
Asymmetric Polyarthritis | Â | Â | Â |
n (%) | 0 | 2 (6.06%) | 0.542** |
Deformities of peripheral joints | Â | Â | Â |
n (%) | 7 (100%) | 15 (45.45%) | 0.011** |
Functional impairment of peripheral joints | Â | Â | Â |
n (%) | 7 (100%) | 15 (45.45%) | 0.011** |
Radiological changes: peripheral deformities/erosions | Â | Â | Â |
n (%) | 7 (100%) | 15 (45.45%) | 0.011** |
RF concentrations (IU/ml) | Â | Â | Â |
Median (range) | 15 (7–30) | 9 (4–33) | 0.0714* |
Anti-CCP concentrations (U/ml) Mean ± SD (range) | 34.7 ± 8 (30–45) | 3.21 ± 1.16 (1–5) | 0.0001* |